No photo of Sanjay Goel

View Scopus Profile

Sanjay Goel, M.B.,B.S.

  • 1678 Citations
  • 22 h-Index
20022019
If you made any changes in Pure, your changes will be visible here soon.

Fingerprint Dive into the research topics where Sanjay Goel is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 13 Similar Profiles
Neoplasms Medicine & Life Sciences
eribulin Medicine & Life Sciences
irinotecan Medicine & Life Sciences
Pharmacokinetics Medicine & Life Sciences
Colorectal Neoplasms Medicine & Life Sciences
oxaliplatin Medicine & Life Sciences
Epidermal Growth Factor Receptor Medicine & Life Sciences
docetaxel Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Publications 2002 2019

  • 1678 Citations
  • 22 h-Index
  • 73 Article
  • 2 Review article
  • 1 Chapter

Anti-PD-1 monoclonal antibody MEDI0680 in a phase i study of patients with advanced solid malignancies

Naing, A., Infante, J., Goel, S., Burris, H., Black, C., Marshall, S., Achour, I., Barbee, S., May, R., Morehouse, C., Pollizzi, K., Song, X., Steele, K., Elgeioushi, N., Walcott, F., Karakunnel, J., Lorusso, P., Weise, A., Eder, J., Curti, B. & 1 others, Oberst, M., Aug 22 2019, In : Journal for ImmunoTherapy of Cancer. 7, 1, 225.

Research output: Contribution to journal › Article

Open Access
Kidney Neoplasms
Melanoma
Pharmacokinetics
Monoclonal Antibodies
T-Lymphocytes

A phase 1b, multicenter, open-label, dose-finding study of eribulin in combination with carboplatin in advanced solid tumors and non-small cell lung cancer

Goel, S., Swami, U., Kumar, K., Dittrich, C., Reyderman, L., Jain, M., Aisner, J., Song, J. & Petrylak, D. P., Jan 1 2019, In : Cancer Chemotherapy and Pharmacology.

Research output: Contribution to journal › Article

eribulin
Carboplatin
Non-Small Cell Lung Carcinoma
Labels
Tumors

A phase I pharmacokinetic study of belinostat in patients with advanced cancers and varying degrees of liver dysfunction

Takebe, N., Beumer, J. H., Kummar, S., Kiesel, B. F., Dowlati, A., O'Sullivan Coyne, G., Piekarz, R., Rubinstein, L., Fogli, L. K., Vaishampayan, U., Goel, S., O'Bryant, C. L., El-Rayes, B. F., Chung, V., Lenz, H. J., Kim, R., Belani, C. P., Tuscano, J. M., Schelman, W., Moore, N. & 2 others, Doroshow, J. H. & Chen, A. P., Jan 1 2019, (Accepted/In press) In : British Journal of Clinical Pharmacology.

Research output: Contribution to journal › Article

Open Access
Liver Diseases
Pharmacokinetics
Neoplasms
Maximum Tolerated Dose
Liver

Excision repair cross-complementing group-1 (ERCC1) induction kinetics and polymorphism are markers of inferior outcome in patients with colorectal cancer treated with oxaliplatin

Rao, D., Mallick, A. B., Augustine, T., Daroqui, C., Jiffry, J., Merla, A., Chaudhary, I., Seetharam, R., Sood, A., Gajavelli, S., Aparo, S., Rajdev, L., Kaubisch, A., Chuy, J., Negassa, A., Mariadason, J. M., Maitra, R. & Goel, S., Jan 1 2019, In : Oncotarget. 10, 53, p. 5510-5522 13 p.

Research output: Contribution to journal › Article

oxaliplatin
DNA Repair
Colorectal Neoplasms
Disease-Free Survival
Single Nucleotide Polymorphism
3 Citations (Scopus)

Novel patterns of response under immunotherapy

Borcoman, E., Kanjanapan, Y., Champiat, S., Kato, S., Servois, V., Kurzrock, R., Goel, S., Bedard, P. & Le Tourneau, C., Mar 1 2019, In : Annals of Oncology. 30, 3, p. 385-396 12 p.

Research output: Contribution to journal › Review article

Open Access
Immunotherapy
Therapeutics
Disease Progression
Melanoma
Neoplasms